Funding Opportunities

• Non-Viral Gene Delivery (for Gene Therapy and Biomanufacturing)

  AMBER are investing up to €2m in the
  development of Non-Viral gene delivery
  platforms. Additional opportunity to work with AMBER and NIBRT on development of stable and scalable nanotechnologies for nucleic acid delivery. Looking for industry partner(s) willing to collaborate on these exciting initiatives with Matched funding.

  Targeted

  

  Source

• Frontiers for the Future

  This bottom-up funding programme provides opportunities for independent investigators to conduct highly innovative, collaborative research with the potential to deliver impact, whilst also providing opportunities for high-risk, high-reward research projects.

  Funder:
  Science Foundation Ireland

  Call Status:
  2022 Call: Projects stream is CLOSED
  2022 Call: Awards stream is OPEN

  Targeted

  

  Source

• Disruptive Technologies Innovation Fund (DTIF) - Call 6

  The Disruptive Technologies Innovation Fund (DTIF) supports businesses in Ireland to exploit the enterprise opportunities associated with disruptive technologies by de-risking projects that have the potential to alter markets, alter the way business operates or involve new products or the emergence of new business models. DTIF funds collaborative projects between enterprises and with research institutions in key technology areas that utilise “industrial research” and/or “experimental development” to demonstrate disruptive innovation.

  DTIF Call 6 is a general Call seeking projects within the six national Research Priority Areas. It encourages projects that complement the priority enterprise policy objectives on digital transformation and integrating decarbonisation and net zero commitments, as set out in the White Paper on Enterprise. Projects that help to drive the innovation and transformation opportunities that are needed in sectors such as construction are also welcomed. However, all projects are expected to demonstrate a positive contribution to the sustainability targets in the Climate Action Plan.

  Funder:
  Enterprise Ireland

  Call Status:
  Call CLOSED

  Untargeted

  

  Source

• Innovation Partnership Programme

  This funding programme encourages Irish-based companies to work with Irish researchers to undertake research which supports the development of new and improved products, processes, services and generate new knowledge and know-how.

  Funder:
  Enterprise Ireland

  Call Status:
  Call OPEN (multiple cut-offs per year)

  Untargeted

  

  Source

• European Innovation Council (EIC) - Pathfinder Challenge Emerging Technologies in Cell and Gene Therapy

  Proposals must focus on emerging technologies or breakthrough new concept-based technological solutions that go far beyond the current state-of-the-art, aimed to overcome cell and gene therapy challenges and obstacles companies are currently being faced with, at the preclinical or clinical level or bio-manufacturing level. Proposers can submit disease or non-disease specific proposals.

  Funder:
  Horizon Europe

  Call Status:
  Call closed (2022)

  Targeted

  

  Source

• European Innovation Council (EIC) - Pathfinder Open

  EIC Pathfinder Open provides funding for projects in any field of science or technology, based on high-risk/high-gain science-towards-technology breakthrough interdisciplinary research.

  Funder:
  Horizon Europe

  Call Status:
  Call closed (4 May 2022)

  Untargeted

  

  Source

• Health Cluster (Destination 3) - Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs (HORIZON-HLTH-2022-DISEASE-06-02-two-stage)

  This topic covers passive and active immunotherapies (such as antibody-based, RNA-based and cell based therapies). Focused on pre-clinical to clinical trials (in vitro and in vivo). Regulatory pathway – proof of concept, regulation to clinical path. Communicable and non-communicable disease – high burden disease. Cance, rare diseases and repurposing of drugs not included in this call.

  Funder:
  Horizon Europe

  Call Status:
  1st stage deadline (1 February 2022), 2nd Stage deadline (6 September 2022)

  Targeted

  

  Source

• Health Cluster (Destination 3) - Vaccines 2.0 - developing the next generation of vaccines (HORIZON-HLTH-2022-DISEASE-06-03-two-stage)

  Proposals should aim to diversify and accelerate the global vaccine research and development pipeline, and to strengthen the current leading role of the EU in vaccine research and development. Proposals should cover those pathogens, which still lack vaccines of sufficient efficacy, but where earlier efforts have already produced promising vaccine candidates. Scope includes deciphering mechanisms of protection of candidates, new approaches to antigen discovery and immunogen engineering, reverse vaccinology, evaluation of vaccines in novel platforms and technologies, novel adjuvants, innovative vaccine manufacturing approaches, relevant animal models, evaluation of alternative vaccine delivery routes.

  Funder:
  Horizon Europe

  Call Status:
  1st stage deadline (1 February 2022), 2nd Stage deadline (6 September 2022)

  Targeted

  

  Source

• Health Cluster (Destination 3) - Development of new effective therapies for rare diseases (HORIZON-HLTH-2022-DISEASE-06-04-two-stage)

  Proposals should aim to develop therapies for rare diseases with no approved therapeutic option and focus on group(s) of rare diseases with commonalities, such as shared biological features. The therapies to be developed may include a broad family of therapeutic interventions such as small molecule(s), advanced therapy medicinal products, repurposing of existing medicinal products including non-pharmacological interventions and/or their combinations, as relevant. This call excludes rare infections and rare cancers and covers pre-clinical proof of concept to late stage pre-clinical studies – with a clear exploitation pathway.

  Funder:
  Horizon Europe

  Call Status:
  1st stage deadline (1 February 2022), 2nd Stage deadline (6 September 2022)

  Targeted

  

  Source

• Health Cluster (Destination 5) - Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet medical needs (HORIZON-HLTH-2021-TOOL-06-02)

  The recent development of advanced therapies has been hampered by the lack of robust research on certain key parameters e.g. safety, upscaling, immunity, potency assays, cost-effectiveness, and early on in development. This topic aims to ensure that the next wave of advanced therapies, based on either pluripotent stem cells, gene editing or RNA, are established in a timely fashion and in accordance with the appropriate regulatory standards for further clinical testing. It will support preclinical research platforms for disorders with high prevalence and burden that tackle the bottlenecks currently encountered in the field, ensuring that promising advanced therapies can reach the market within the next decade.

  Funder:
  Horizon Europe

  Call Status:
  Call closed (21 September 2021)

  Targeted

  

  Source

• European Research Council

  The fundamental focus of the ERC through its main frontier research grants (e.g. Starter, Consolidator and Advanced Grants) is to provide attractive, long-term funding to support excellent investigators and their research teams to pursue ground-breaking high-gain/high-risk research. Research funded by the ERC is expected to lead to advances at the frontiers of knowledge and to set a clear and inspirational target for frontier research across Europe.

  Funder:
  Horizon Europe

  Call Status:
  Starting Grant 2022 call closed (13 Jan 2022); next call deadline 25 October 2022 (anticipated) Consolidator Grant 2022 call closed (17 March 2022); next call deadline 2 February 2023 (anticipated) Advanced Grant 2022 call closed (28 April 2022); next call deadline 23 May 2023 (anticipated)

  Untargeted

  

  Source